Morris, Michael J.

Publications

Sort by

Co-Author Network

selected publications

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 7
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 79
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology. 2019 Review GET IT
Times cited: 30
Pharmacokinetics and Biodistribution of a [⁸⁹Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients. Molecular pharmaceutics. 2019 Academic Article GET IT
Times cited: 21
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 33
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 32
Assessment of Simplified Methods for Quantification of ¹⁸F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 8
Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply. JAMA oncology. 2019 Comment GET IT
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 142
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 65
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate. 2018 Review GET IT
Times cited: 30
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA oncology. 2018 Academic Article GET IT
Times cited: 37
Reproducibility and Repeatability of Semiquantitative ¹⁸F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 14
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2018 GET IT
Times cited: 42
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Review GET IT
Times cited: 100
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Review GET IT
Times cited: 54
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 71
Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?. Cancer. 2018 Review GET IT
Times cited: 32
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 6
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. The oncologist. 2017 Academic Article GET IT
Times cited: 54
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 60
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European urology. 2017 Conference Paper GET IT
Times cited: 367
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2017 Academic Article GET IT
Times cited: 29
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2016 Academic Article GET IT
Times cited: 39
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 502
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223. The Prostate. 2016 Review GET IT
Times cited: 4
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic oncology. 2016 Academic Article GET IT
Times cited: 36
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 16
Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 9
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 92
A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 24
Repeatability of Quantitative 18F-NaF PET: A Multicenter Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 49
Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. Journal of labelled compounds & radiopharmaceuticals. 2016 Academic Article GET IT
Times cited: 9
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 39
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. Prostate cancer and prostatic diseases. 2016 Academic Article GET IT
Times cited: 4
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI research. 2016 Academic Article GET IT
Times cited: 1825
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Review GET IT
Times cited: 264
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Conference Paper GET IT
Times cited: 881
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 15
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016 Academic Article GET IT
Times cited: 24
Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancer journal (Sudbury, Mass.). 2016 Review GET IT
Times cited: 14
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Academic Article GET IT
Times cited: 15
Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 Academic Article GET IT
Times cited: 40
Reply to K. Lu. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Letter GET IT
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 2015 Article GET IT
Times cited: 340
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer. 2015 Academic Article GET IT
Times cited: 24
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
Integrative clinical genomics of advanced prostate cancer. Cell. 2015 Academic Article GET IT
Times cited: 2094
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI research. 2015 Academic Article GET IT
Times cited: 111
Targeting the androgen receptor in prostate and breast cancer: several new agents in development. Endocrine-related cancer. 2015 Review GET IT
Times cited: 78
Failure of ELM-PC 5: an ineffective drug or an unfit end point?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Editorial Article GET IT
Times cited: 5
Response. Radiology. 2015 Letter GET IT
Times cited: 4
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 110
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. 2014 GET IT
Times cited: 24
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2014 Academic Article GET IT
Times cited: 25
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urologic oncology. 2014 Academic Article GET IT
Times cited: 43
Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014 Academic Article GET IT
Times cited: 983
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2014 Academic Article GET IT
Times cited: 112
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer. Health physics. 2014 Academic Article GET IT
Times cited: 50
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 193
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 351
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2013 Academic Article GET IT
Times cited: 78
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 190
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 203
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Academic Article GET IT
Times cited: 17
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013 Academic Article GET IT
Times cited: 21
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?. Seminars in oncology. 2013 Review GET IT
Times cited: 32
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 321
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2013 Academic Article GET IT
Times cited: 144
Validation and clinical utility of prostate cancer biomarkers. Nature reviews. Clinical oncology. 2013 Review GET IT
Times cited: 69
Targeting bone physiology for the treatment of metastatic prostate cancer. Clinical advances in hematology & oncology : H&O. 2013 Review GET IT
Times cited: 11
Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2012 Academic Article GET IT
Times cited: 57
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. Journal of the National Cancer Institute. 2012 Academic Article GET IT
Times cited: 106
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Current treatment options in oncology. 2012 Review GET IT
Times cited: 27
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 29
Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nuclear medicine communications. 2012 Academic Article GET IT
Times cited: 40
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 368
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen. 2012 GET IT
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. European urology. 2012 Academic Article GET IT
Times cited: 141
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. Cancer. 2012 Academic Article GET IT
Times cited: 65
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 136
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 28
Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2011 Academic Article GET IT
Times cited: 69
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 21
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 Academic Article GET IT
Times cited: 39
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 187
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic oncology. 2011 Academic Article GET IT
Times cited: 47
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU international. 2011 Academic Article GET IT
Times cited: 38
Developing imaging strategies for castration resistant prostate cancer. Acta oncologica (Stockholm, Sweden). 2011 Academic Article GET IT
Times cited: 39
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 38
Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 57
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 104
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. PloS one. 2010 Academic Article GET IT
Times cited: 13
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Annals of internal medicine. 2010 Academic Article GET IT
Times cited: 42
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (London, England). 2010 Academic Article GET IT
Times cited: 924
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 222
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 379
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 100
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 190
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 80
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. European urology. 2009 Academic Article GET IT
Times cited: 71
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clinical genitourinary cancer. 2009 Academic Article GET IT
Times cited: 20
Novel tracers and their development for the imaging of metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008 Review GET IT
Times cited: 106
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. British journal of cancer. 2008 Academic Article GET IT
Times cited: 12
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Academic Article GET IT
Times cited: 18
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 23
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2008 Academic Article GET IT
Times cited: 67
Expression of prostate-specific membrane antigen in renal cortical tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2008 Academic Article GET IT
Times cited: 32
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 2008 GET IT
Times cited: 1830
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. The Journal of urology. 2007 Academic Article GET IT
Times cited: 36
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 78
Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions. The Journal of urology. 2007 Academic Article GET IT
Times cited: 6
Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. The Journal of urology. 2007 Conference Paper GET IT
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer immunology, immunotherapy : CII. 2007 Academic Article GET IT
Times cited: 65
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 71
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 189
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 89
Rapid androgen cycling as treatment for patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 22
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nature clinical practice. Oncology. 2006 Review GET IT
Times cited: 53
Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. Nature clinical practice. Oncology. 2006 Academic Article GET IT
Times cited: 1
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 110
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Review GET IT
Times cited: 116
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen. Urology. 2005 Academic Article GET IT
Times cited: 7
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 105
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Current urology reports. 2005 Review GET IT
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Applied immunohistochemistry & molecular morphology : AIMM. 2005 Academic Article GET IT
Times cited: 23
Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magnetic resonance in medicine. 2004 Academic Article GET IT
Times cited: 63
PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 76
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 31
Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Current oncology reports. 2004 Review GET IT
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 292
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 2004 GET IT
Times cited: 178
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 34
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Academic Article GET IT
Times cited: 63
Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center. Critical reviews in oncology/hematology. 2003 Review GET IT
Times cited: 5
Clinical approaches to osseous metastases in prostate cancer. The oncologist. 2003 Review GET IT
Times cited: 27
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology. 2002 Review GET IT
Times cited: 13
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002 Academic Article GET IT
Times cited: 180
Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies. Surgical oncology. 2002 Review GET IT
Times cited: 14
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 178
HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 125
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 143
Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer. 2000 Review GET IT
Times cited: 46
Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. 2000 GET IT
Times cited: 41
High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: the Memorial Sloan-Kettering experience (1988-1999). International journal of cancer. 1999 Academic Article GET IT
Times cited: 19

more ...

less ...

Background

education and training

M.D., Mount Sinai School of Medicine 1994
B.A., Harvard University 1987

Contact

full name

Michael J. Morris

VIVO Weill Cornell Medical College

Michael J. Morris Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name